Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial
Findings from a novel study supports the JAK inhibitor tofacitinib as a potential first-line therapy for ASUC.
Read More
A Review of Upadacitinib in Crohn’s Disease: A Promising JAK1 Inhibitor
The Cleveland Clinic fellow explains why is upadacitinib is an essential tool in treating Crohn’s disease, especially in those who have previously failed conventional or biologic therapies.
Upadacitinib: An Evolving Treatment for Ulcerative Colitis
The inhibition of Janus kinase to prevent downstream signaling of proinflammatory cytokines has been shown to be a novel method of treating ulcerative colitis.